stonks4u
Sign up free
MESO logo

MESO Mesoblast Limited

NASDAQ Global Select · Biotechnology · Healthcare

$15.60
-0.90 (-5.43%)

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-medi…

Market Cap: $2.02Bwww.mesoblast.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 16Aug 16

Quote

Day Range
$15.40 – $15.62
52-Week Range
$12.66 – $21.50
Volume
$164.8K
Market Cap
$2.02B
50-Day Avg
$15.11
200-Day Avg
$16.00
Prev Close
$16.49
Open
$15.56

Valuation & Ratios

P/E Ratio
-12.90
EPS
$-0.85
P/B Ratio
2.20
P/S Ratio
76.48
Debt/Equity
0.21
Current Ratio
1.99
Dividend Yield
+0.0%
Gross Margin
+70.2%

Returns & Efficiency

Return on Equity
-17.1%
Return on Assets
-13.0%
FCF Yield
-3.9%
EV/EBITDA
-17.41

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$17.20M$-102.14M$-0.84
2024$5.90M$-87.96M$-0.89
2023$7.50M$-81.89M$-0.98
2022$10.21M$-91.35M$-1.30
2021$7.46M$-98.81M$-1.60

Social Signal Score

70
5d
71
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1

Earnings

Fri, Sep 4(in 3 weeks)

Consensus estimate $-0.11 per share

3of 7 quarters beat consensus

Typical surprise -15.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Feb 26$-0.31 vs $-0.24miss
  • Thu, Aug 28$-0.32 vs $-0.20miss
  • Tue, Jul 29$-0.43 vs $-0.37miss
  • Wed, Apr 30$-0.21 vs $-0.35beat
  • Wed, Feb 26$-0.42 vs $-0.25miss
  • Wed, Oct 30$-0.28 vs $-0.31beat

Estimates and results for MESO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by MESO officers and directors.

Bought
$19.9m

26 trades

Sold
—

0 trades

  • George Gregorybought
    director, 10 percent owner:·2,324,072 @ $1.48·$3.4m·Apr 10, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·10,000 @ $1.41·$14k·Apr 9, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·10,000 @ $1.43·$14k·Apr 9, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·10,000 @ $1.43·$14k·Apr 9, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·5,000 @ $1.43·$7k·Apr 9, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·10,000 @ $1.43·$14k·Apr 9, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·5,240 @ $1.43·$7k·Apr 9, 2026·filing
  • George Gregorybought
    director, 10 percent owner:·10,000 @ $1.43·$14k·Apr 9, 2026·filing

53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

MESOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5h ago·Positive

    …Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. T…

    View source ↗